Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $1.14 USD
Change Today +0.01 / 0.88%
Volume 212.5K
EKSO On Other Exchanges
As of 8:10 PM 10/2/15 All times are local (Market data is delayed by at least 15 minutes).

ekso bionics holdings inc (EKSO) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/1/15 - $2.34
52 Week Low
08/17/15 - $0.93
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

ekso bionics holdings inc (EKSO) Related Bloomberg News

View More Bloomberg News

ekso bionics holdings inc (EKSO) Related Businessweek News

No Related Businessweek News Found

ekso bionics holdings inc (EKSO) Details

Ekso Bionics Holdings, Inc. designs, develops, and sells wearable robots or exoskeletons for use in the medical, military, industrial, and consumer markets in North America, Western Europe, the Middle East, and South Africa. The company operates through Engineering Services and Medical segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, stroke, and other lower-extremity paralysis or weakness. The company’s Ekso device is primarily used in a clinic or rehabilitation setting. It also performs research and development work on human exoskeletons and related technologies. The company has a collaborative partnership with Lockheed Martin Corporation to develop products for military applications, as well as a license agreement with Otto Bock Healthcare Products Gmbh. Ekso Bionics Holdings, Inc. was founded in 2005 and is headquartered in Richmond, California.

67 Employees
Last Reported Date: 04/6/15
Founded in 2005

ekso bionics holdings inc (EKSO) Top Compensated Officers

Co-Founder, Chief Executive Officer and Direc...
Total Annual Compensation: $401.1K
President and Chief Commercial Officer
Total Annual Compensation: $201.7K
Co-Founder and President of Ekso Labs Divisio...
Total Annual Compensation: $323.0K
Chief Financial Officer
Total Annual Compensation: $323.0K
Compensation as of Fiscal Year 2014.

ekso bionics holdings inc (EKSO) Key Developments

Ekso Bionics Holdings Announces Board Appointments

Ekso Bionics Holdings, Inc. announced the appointment of industry veteran Ruediger Hausherr to meet the needs of its expanding European markets. Mr. Hausherr has over 20 years’ experience bringing novel new therapies to market in executive leadership positions in the Orthopedic field; including having served as CEO/shareholder for ORMED GmbH, which is now a DJO Global company. He also currently serves as Board member for several healthcare companies worldwide, contributing to his broad base of industry know-how and market knowledge. To service the increase in clinical demand for its medical exoskeleton (Ekso GT(TM)), the company has also brought on board Mr. Marco Sauer as Sales Manager and Mr. Sebastian Stallasch as Clinical Specialist Therapist. Mr. Sauer will be responsible for driving sales in German-speaking countries and Mr. Stallasch will be responsible for therapeutic evaluation of potential patients and training physical therapists on the Ekso GT as part of the company's expansion efforts.

Ekso Bionics Holdings, Inc. Presents at Ladenburg Thalmann 2015 Healthcare Conference, Sep-29-2015 09:30 AM

Ekso Bionics Holdings, Inc. Presents at Ladenburg Thalmann 2015 Healthcare Conference, Sep-29-2015 09:30 AM. Venue: Sofitel Hotel, New York, New York, United States. Speakers: Nathan Harding, Co-Founder, Chief Executive Officer and Director.

Ekso Bionics Holdings, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Ekso Bionics Holdings, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company's total revenue was $2,114,000 against $1,197,000 a year ago. Loss from operations was $5,635,000 against $4,312,000 a year ago. Net loss was $5,645,000 or $0.06 diluted per share against income of $56,128,000 or $0.05 diluted per share a year ago. For the six months, the company's total revenue was $3,803,000 against $2,259,000 a year ago. Loss from operations was $9,728,000 against $8,203,000 a year ago. Net loss was $9,760,000 or $0.10 diluted per share against $25,638,000 or $0.35 diluted per share a year ago. Net cash used in operating activities was $8,462,000 against $8,605,000 a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EKSO:US $1.14 USD +0.01

EKSO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CYBERDYNE Inc ¥1,430 JPY +3.00
Parker-Hannifin Corp $98.14 USD +2.09
ReWalk Robotics Ltd $8.10 USD +0.27
Rex Bionics PLC 50.00 GBp 0.00
View Industry Companies

Industry Analysis


Industry Average

Valuation EKSO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 16.9x
Price/Book 8.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 14.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EKSO BIONICS HOLDINGS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at